Detailed information for compound 449912
Basic information
Technical information
- TDR Targets ID: 449912
- Name: 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-m orpholin-4-yl-3,4-dihydropyrazole-5-carboxami de; sulfuric acid
- MW: 551.828 | Formula: C20H21Cl3N4O6S
-
H donors: 3
H acceptors: 5
LogP: 0.83
Rotable bonds: 5
Rule of 5 violations (Lipinski): 2 - SMILES: OS(=O)(=O)O.Clc1ccc(cc1)C1CC(=NN1c1ccc(cc1Cl)Cl)C(=O)NN1CCOCC1
- InChi: 1S/C20H19Cl3N4O2.H2O4S/c21-14-3-1-13(2-4-14)19-12-17(20(28)25-26-7-9-29-10-8-26)24-27(19)18-6-5-15(22)11-16(18)23;1-5(2,3)4/h1-6,11,19H,7-10,12H2,(H,25,28);(H2,1,2,3,4)
- InChiKey: OBPAVQCOFPPHAN-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-morpholino-3,4-dihydropyrazole-5-carboxamide; sulfuric acid
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-morpholino-2-pyrazoline-3-carboxamide; sulfuric acid
- 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-morpholin-4-ium-4-yl-3,4-dihydropyrazole-5-carboxamide; hydrogen sulfate
- 3-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-N-(4-morpholin-4-iumyl)-3,4-dihydropyrazole-5-carboxamide; hydrogen sulfate
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-morpholin-4-ium-4-yl-2-pyrazoline-3-carboxamide bisulfate
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-morpholin-4-ium-4-yl-4,5-dihydropyrazole-3-carboxamide; hydrogen sulfate
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-(4-morpholin-4-iumyl)-4,5-dihydropyrazole-3-carboxamide; hydrogen sulfate
- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-N-morpholin-4-ium-4-yl-4,5-dihydropyrazole-3-carboxamide bisulfate
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Homo sapiens | cannabinoid receptor 1 (brain) | Starlite/ChEMBL | References |
| Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | Curated by TDR Targets | References |
Predicted pathogen targets for this compound
By orthology
| Species | Potential target | Known druggable target/s | Ortholog Group |
|---|---|---|---|
| Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | Get druggable targets OG5_132746 | All targets in OG5_132746 |
| Mycobacterium ulcerans | 3-dehydroquinate dehydratase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
| Candida albicans | 3-dehydroquinate dehydratase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
| Candida albicans | 3-dehydroquinase | Get druggable targets OG5_132746 | All targets in OG5_132746 |
| Mycobacterium leprae | 3-dehydroquinate dehydratase AroD (AroQ) (3-dehydroquinase) (Type II DHQase) | Get druggable targets OG5_132746 | All targets in OG5_132746 |
By sequence similarity to non orthologous known druggable targets
| Species | Potential target | Known druggable target | Length | Alignment span | Identity |
|---|---|---|---|---|---|
| Mycobacterium tuberculosis | Possible alanine rich transferase | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | 147 aa | 148 aa | 26.4 % |
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium tuberculosis | 3-dehydroquinate dehydratase AroD (AROQ) (3-dehydroquinase) (type II dhqase) | 0.1429 | 0.5 | 0.5 |
| Mycobacterium ulcerans | 3-dehydroquinate dehydratase | 0.1429 | 0.5 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | 0 | Inhibition of body weight gain in Zucker fa/fa rat at 10 mg/kg, po | ChEMBL. | 17979261 |
| Activity (functional) | 0 | Reduction in serum triglyceride level in Zucker fa/fa rat at 10 mg/kg, po after 60 days | ChEMBL. | 17979261 |
| Activity (functional) | = 0.4 | Effect on locomotor activity in Swiss albino mouse tetrad model assessed as number of squares crossed in 5 mins at 1 mg/kg, po after 35 mins in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 3 | Effect on locomotor activity in Swiss albino mouse tetrad model assessed as number of squares crossed in 5 mins at 3 mg/kg, po after 35 mins in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 13.25 | Effect on locomotor activity in Swiss albino mouse tetrad model assessed as number of squares crossed in 5 mins at 10 mg/kg, po after 35 mins in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 25 | Effect on locomotor activity in Swiss albino mouse tetrad model assessed as number of squares crossed in 5 mins at 30 mg/kg, po after 35 mins in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 14.2 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 10 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 14.2 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 10 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 18.23 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 30 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 18.23 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 30 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 33.75 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 3 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 33.75 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 3 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 85.2 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 1 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 85.2 % | Effect on catalepsy in Swiss albino mouse tetrad model assessed as immobility for 5 mins at 1 mg/kg, po after 30 mins by ring test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -4.24 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 1 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -4.24 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 1 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -2.1 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 3 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -2.1 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 3 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -0.15 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 10 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = -0.15 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 10 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 0.15 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 30 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Activity (functional) | = 0.15 degrees C | Effect on change in body temperature in Swiss albino mouse tetrad model at 30 mg/kg, po in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| AUC (ADMET) | = 10 ug.hr/ml | AUC (0 to infinity) in fasted Zucker fa/fa rat at 30 mg/kg, po | ChEMBL. | 17979261 |
| Cmax (ADMET) | = 0.51 ug ml-1 | Cmax in fasted Zucker fa/fa rat at 30 mg/kg, po | ChEMBL. | 17979261 |
| Cp (ADMET) | = 1.4 ug ml-1 | Drug concentration in fasted Zucker fa/fa rat plasma at 30 mg/kg, po after 3 hrs | ChEMBL. | 17979261 |
| Drug uptake (ADMET) | = 4.86 ug/g | Drug concentration in fasted Zucker fa/fa rat brain at 30 mg/kg, po after 3 hrs | ChEMBL. | 17979261 |
| Drug uptake (ADMET) | = 6.31 ug/g | Drug concentration in fasted Zucker fa/fa rat white adipose tissue at 30 mg/kg, po after 3 hrs | ChEMBL. | 17979261 |
| Inhibition (functional) | = 15.4 % | Inhibition of sucrose intake in Zucker fa/fa rat at 10 mg/kg, po after 4 hrs | ChEMBL. | 17979261 |
| Inhibition (functional) | = 36.4 % | Inhibition of sucrose intake in Zucker fa/fa rat at 10 mg/kg, po after 4 hrs | ChEMBL. | 17979261 |
| Inhibition (functional) | = 58.6 % | Inhibition of sucrose intake in Zucker fa/fa rat at 10 mg/kg, po after 4 hrs | ChEMBL. | 17979261 |
| Ki (binding) | = 0.15 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 0.15 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 0.334 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 0.334 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 0.475 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 0.475 uM | Displacement of [3H]CP55940 from human recombinant CB1 receptor expressed in HEK293 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 21.7 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 21.7 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 24.5 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 24.5 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 26.4 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| Ki (binding) | = 26.4 uM | Displacement of [3H]WIN552122 from human recombinant CB2 receptor expressed in CHOK1 cells | ChEMBL. | 17979261 |
| MPE (functional) | = -0.15 % | Analgesic activity in Swiss albino mouse tetrad model at 10 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = -0.15 % | Analgesic activity in Swiss albino mouse tetrad model at 10 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 11.5 % | Analgesic activity in Swiss albino mouse tetrad model at 30 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 11.5 % | Analgesic activity in Swiss albino mouse tetrad model at 30 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 12 % | Analgesic activity in Swiss albino mouse tetrad model at 3 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 12 % | Analgesic activity in Swiss albino mouse tetrad model at 3 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 24 % | Analgesic activity in Swiss albino mouse tetrad model at 1 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| MPE (functional) | = 24 % | Analgesic activity in Swiss albino mouse tetrad model at 1 mg/kg, po by hot plate test in presence of 1 mg/kg cannabinoid agonist WIN-55212-2 relative to control | ChEMBL. | 17979261 |
| Ratio Ki (binding) | = 163 | Selectivity for human recombinant CB2 receptor over human recombinant CB1 receptor | ChEMBL. | 17979261 |
| t1/2 (ADMET) | = 17.61 hr | Half life in fasted Zucker fa/fa rat at 30 mg/kg, po | ChEMBL. | 17979261 |
| Tmax (ADMET) | = 3.7 hr | Tmax in fasted Zucker fa/fa rat at 30 mg/kg, po | ChEMBL. | 17979261 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL239703
- PubChem: 24180552
- PubChem: 25047699
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.